Spinogenix, Inc.
Spinogenix is pioneering first-in-class, investigational therapeutics that restore brain synapses to improve the lives of patients worldwide.
Funding history
About Spinogenix, Inc.
How much funding has Spinogenix, Inc. raised?
Spinogenix, Inc. has raised $18.6M in total funding. The most recent round was Seed.
Where is Spinogenix, Inc. headquartered?
Spinogenix, Inc. is headquartered in La Jolla, CA.
What does Spinogenix, Inc. do?
Spinogenix is pioneering first-in-class, investigational therapeutics that restore brain synapses to improve the lives of patients worldwide.
What problem does Spinogenix, Inc. solve?
Neurodegenerative, neuropsychiatric, and neurodevelopmental conditions such as ALS, Alzheimer's, schizophrenia, and Fragile X Syndrome involve a loss of brain synapses.
What's Spinogenix, Inc.'s solution?
Develops investigational small-molecule therapeutics designed to restore brain synapses in patients with these conditions.
What makes Spinogenix, Inc. different?
Describes its drugs as first-in-class synaptic regenerative therapies, citing positive Phase IIa data in ALS and durable benefits in Alzheimer's patients treated up to 84 weeks.
What makes Spinogenix, Inc. notable?
Founded by Dr. Stella Sarraf; its ALS drug candidate SPG302 received an FDA-authorized expanded access program in 2025.
Leadership
Related terms
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated September 3, 2026.
🏷 Embed this badge
Building or fundraising? Add this to your site to show you're listed on SoCal.Startups — the link back helps other founders and investors find you here too.
